Randomized, controlled trial of transdermal clonidine for smoking cessation

Daniel E. Hilleman, Syed M. Mohiuddin, Michael G. Delcore, B. Daniel Lucas

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (

Original languageEnglish (US)
Pages (from-to)1025-1028
Number of pages4
JournalAnnals of Pharmacotherapy
Issue number9
StatePublished - Sep 1993

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)


Dive into the research topics of 'Randomized, controlled trial of transdermal clonidine for smoking cessation'. Together they form a unique fingerprint.

Cite this